Intensity-modulated ventricular irradiation for intracranial germ-cell tumors: Survival analysis and impact of salvage re-irradiation

Ana Carolina Pires de Rezende1*, Eduardo Weltman1,2, Michael Jenwei Chen3, Juliana Karassawa Helito1, Ícaro Thiago de Carvalho1, Roberto Kenji Sakuraba1, Nasjla Saba Silva4, Andrea Maria Cappellano4, Nelson Hamerschlak5

1 Department of Radiation Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil, 2 Department of Radiation Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3 Department of Radiation Oncology, Instituto de Oncologia Pediátrica - Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC) da Universidade Federal de São Paulo, Sao Paulo, Brazil, 4 Department of Pediatric Oncology, Instituto de Oncologia Pediátrica - Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC) da Universidade Federal de São Paulo, Sao Paulo, Brazil, 5 Department of Hematology and Clinical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil

* ana.rezende@einstein.br

Abstract

Background and purpose
The roles of surgery, chemotherapy, and parameters of radiation therapy for treating very rare central nervous system germ cell tumors (CNS-GCT) are still under discussion. We aimed to evaluate the survival and recurrence patterns of patients with CNS-GCT treated with chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy.

Materials and methods
We reviewed the clinical outcomes of 20 consecutive patients with CNS-GCT treated with chemotherapy and intensity-modulated radiation therapy from 2004 to 2014 in two partner institutions.

Results
Twenty children with a median age of 12 years were included (16 males). Sixteen tumors were pure germinomas, and 4 were non-germinomatous germ cell tumors (NGGCT). All patients were treated with intensity-modulated radiation therapy guided by daily images, and 70% with volumetric intensity-modulated arc radiotherapy additionally. The median dose for the whole-ventricle was 25.2 Gy (range: 18–30.6 Gy) and 36 Gy (range: 30–54 Gy) for the tumor bed boost. The median post-radiation therapy follow-up was 57.5 months. There were 3 recurrences (2 NGGCT and 1 germinoma that recurred as a NGGCT), with 1 death from the disease and the other 2 cases each successfully rescued with chemotherapy and craniospinal irradiation. The overall survival at 5 years was 95% and disease-free survival was 85%.
Conclusions

The results of this study suggest that the combined use of chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy is effective for CNS-GCTs, especially pure germinomas. Even being rescued with craniospinal irradiation, the NGGCT cases have markedly worse prognoses and should be more rigorously selected for localized treatment.

Introduction

Central nervous system germ cell tumors (CNS-GCT) are a very rare, heterogeneous group of malignancies consisting of histological subtypes with different prognostic profiles [1]. They account for 3% of pediatric brain tumors, except in Asian countries, where the incidence increases to 11% [2–4]. The World Health Organization classifies CNS-GCT into two histological subgroups with high prognostic value: pure germinomas (PG) and non-germinomatomous germ cell tumors (NGGCT) [5]. PG are more common, representing around two-thirds of CNS-GCT, and have a more favorable prognosis. NGGCT include all GCT with some germinoid component of malignancy and/or any tumor that secretes alpha-fetoprotein (AFP) or high levels (> 100–200 IU) of ß-human chorionic gonadotropin (ß-HCG) [6,7].

Treatment of CNS-GCT is still controversial with discussions on how to establish histology parameters, the roles of surgery, chemotherapy (CT), and radiation therapy (RT). Studies have aimed to reduce treatment intensity, either by the exclusive use of CT, or of CT combined with restricted radiation volumes covering only the tumor bed. However, the disease recurrence rates were found unacceptable, reaching 48% when RT was omitted, and the use of irradiation in very focal volumes (i.e. only the tumor bed) resulted in high recurrence rates in the non-irradiated ventricular regions [8–10]. The current trend is to use neoadjuvant CT (regimens based on carboplatin and etoposide with or without ifosfamide). Patients with a good response are offered a consolidative treatment with whole ventricle irradiation followed by a tumor bed boost [11,12]. There are ongoing studies, such as the ACNS1123 of the Children’s Oncology Group—COG (NCT01602666), aiming to reduce radiation doses given to these children without compromising the high cure rates. However, preliminary results are not expected to become available until 2024.

The neurocognitive effects of cranial RT in children have been studied under various scenarios. In CNS prophylaxis for acute lymphoblast leukemia, the use of 24 Gy of radiation to the whole brain (combined with intrathecal CT with methotrexate) has been associated with a reduction of the intelligence quotient (IQ) 5 years following RT, poor scholar performance, a worsening perception of self-image, and higher rates of psychological distress [13]. Related toxicities were reduced (or not detected) when doses of 14–18 Gy were administered. In medulloblastomas, the post-RT IQs were 10–15 points better with whole brain doses of 23.5 Gy compared with 36 Gy [14]. The differences among study conclusions can be explained by the inability of some series to correlate the complex interactions between the dose, the volume, and the patient’s age, with a longer follow-up. Merchant et al. suggested that different regions of the brain, especially the supratentorial area, are important in the development of the cognitive decline associated with RT [15].

The use of technology is necessary to minimize secondary toxicities due to radiation. Compared with conventional or three-dimensional conformal radiotherapy (3D-RT) intensity-modulated radiation therapy (IMRT) is a technique capable of delivering the prescribed dose...
Intensity-modulated ventricular irradiation for intracranial germ-cell tumors

Materials and methods

Study design and ethics

In this retrospective study, we reviewed the medical records of all consecutive patients diagnosed between 2004 and 2014 with CNS-GCT (n = 20). These patients were treated with whole ventricle irradiation using IMRT in two institutions, collaborating through a public-private partnership, in São Paulo, Brazil. The Ethics committee of both hospitals (Hospital Israelita Albert Einstein and Grupo de Apoio ao Adolescente e à Criança com Câncer, GRAACC) where the children were treated approved the protocol of this study, which was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The legal guardians provided written informed consent for treatment. Consent for inclusion in this study was waived since this was a retrospective study based on medical records, and no patient was identified.

Patients and treatments

All patients went through the following staging procedures before starting treatment: brain and spine MRI, baseline ophthalmologic exam, CSF cytology, serum and CSF markers (β-HCG and AFP). All cases were treated aiming for a curative goal using neoadjuvant CT and, prior to RT, 8 patients underwent surgical resection. Drug protocols are described in Table 1.

RT was delivered to the whole ventricular system, using IMRT followed by a boost dose only to the tumor bed. Two patients did not receive this boost. Before starting radiation therapy, all patients underwent a simulation procedure with a thermoplastic mask immobilization, followed by computed tomography (CT) of the area. Images generated were transferred to a computerized planning system (Eclipse—Varian Medical Systems, Palo Alto, CA) to be digitally merged with pre- and post-chemotherapy diagnostic magnetic resonance imaging (MRI).

The prescribed dose-fraction, including the tumor bed boost, varied from 1.5 to 2 Gy per day, with 5 fractions per week. The gross target volume (GTV) corresponded to the primary

| Table 1. Chemotherapy protocols used, according to histological type. |
|---------------------------------------------------------------|
| Germimomas | Carboplatin | 300 mg/m²/day |
|            | Etoposide    | 225 mg/m²/day |
| Germ cell tumors | Carboplatin | 300 mg/m²/day |
| Cycles 1, 3, and 5 | Etoposide    | 225 mg/m²/day |
| Cycles 2, 4, and 6 | Cyclophosphamide | 1.2 g/m²/day |
|                  | Etoposide    | 225 mg/m²/day |

https://doi.org/10.1371/journal.pone.0226350.t001
lesion detected in the first diagnostic MRI added to any residual disease remaining after the initial therapy, as detected in the most recent restaging MRI. In cases of total remission following CT and/or surgery, the GTV corresponded, exclusively, to the site of the primary lesion detected in the first diagnostic MRI. For the tumor bed boost, a clinical target volume (CTV) was created corresponding to the GTV with additional margins of 1.0 to 1.5 cm. For ventricular irradiation, the CTV corresponded to the whole ventricular system, with an additional volumetric margin of 0.3 to 0.5 cm added. Additional 0.3 to 0.5 cm margins were applied to the CTV for each planning target volume (PTV).

All treatments were performed with a 6 MV linear accelerator (23EX, Varian Medical Systems), using the dynamic IMRT technique (sliding window) or volumetric intensity-modulated arc radiotherapy (VMAT), all guided by daily images (IGRT). The plans were calculated using Eclipse software according to the medical prescriptions for target volumes, respecting the pre-established restrictions from the dose-volume histograms, according to Emami et al. [19]. Dosimetric quality controls were conducted using an ionization chamber and portal dosimetry. Besides receiving a technically homogeneous radiation treatment, all patients were followed by the same team of radiation oncologists and pediatric oncologists, with the same protocol of neoadjuvant CT.

Endpoint analysis
The endpoints analyzed included overall survival, disease-free survival, recurrence patterns, and the impact of salvage RT (re-irradiation) in controlling the recurrent disease. Overall survival was defined as survival from the date of diagnosis to the date of death by any cause, excluding patients who were alive at the time of analysis. Disease-free survival was defined as survival from the date of diagnosis to the recurrence date recorded in the medical chart. The pattern of recurrences was described by histological type, radiological presentation, and changes in serum and/or fluid markers. The impact of salvage irradiation was evaluated with radiological parameters and by the normalization of tumor markers after treatment.

Statistical analysis
Patient characteristics were described using the average, standard deviation, median, minimum, and maximum values for the quantitative variables and absolute and relative frequencies for the qualitative variables. The probabilities of overall survival and disease-free survival were estimated using the Kaplan-Meier method.

Results
In this retrospective study, all 20 admitted patients completed their planned treatment and were thus eligible for the evaluation. The median age at the beginning of RT was 12 years old (range: 6 to 18 years), and 16 patients (80%) were male. The location of the tumors was pineal in 8 patients, suprasellar in 7, and pineal and suprasellar in 5. Sixteen patients were diagnosed with a PG (1 with a teratoma with germinomatous microfoci) and 4 with NGGCT (2 with mixed tumors). All patients had only localized intracranial disease, without evidence of cytological dissemination in the cerebrospinal fluid (CSF) or the neuraxis MRI. Six patients had positive tumor markers (β-HCG and/or AFP) in the CSF at diagnosis.

At the end of the neoadjuvant CT, 15 patients were in complete remission from the disease. Of the 5 remaining patients with residual intracranial lesions, 2 underwent surgical resection while the other 3 had residual lesions not amenable for resection. The 20 patients were treated with whole ventricle IMRT using daily IGRT, and the VMAT technique was used in 70%. Only 2 patients did not receive a tumor bed boost. The median dose delivered to the
ventricular fields was 25.2 Gy (range: 18 to 30.6 Gy) and the median dose to the tumor bed was 36 Gy (range: 30 to 54 Gy). The general characteristics of the 20 patients are summarized in Table 2.

The median post-RT follow-up time was 57.5 months (range: 26.4 to 127.9 months). Overall survival was 95%, and disease-free survival was 85% (Fig 1). Considering the two different groups with markedly different prognosis, the PGs presented an overall survival of 100% and disease-free survival of 93.75%, while the NGGCT had an overall survival of 75% with disease-free survival of 50%.

During this period, 3 recurrences were observed with only 1 death from the disease. All recurrence cases were dosimetrically reviewed, showing a good radiation dose distribution with at least 95% of the targeted volumes covered by 95% of the prescribed dose. Two patients with recurrent disease were initially NGGCT, with positive serum and CSF markers at diagnosis. The other case was originally a germinoma (with serum β-HCG < 50 mIU/ml, negative serum AFP and negative CSF markers and cytology) that recurred as a NGGCT with positive serum and CSF markers (both β-HCG and AFP) and CSF positive cytology. (Fig 2).

All recurrences were located in the neuraxis and were positive for CSF markers. Two of these patients also presented new lesions in the brain and spinal cord. The recurrences appeared within the first 6 months in 2 cases and only after 16 months in the third case. One

Table 2. Characteristics of the patients studied.

| Variable                              | Frequency (n = 20) |
|---------------------------------------|-------------------|
| Sex (male), n (%)                     | 16 (80)           |
| Age (years)                           |                   |
| mean (SD)                             | 11.8 (3.4)        |
| median (min.; max.)                   | 12 (6; 18)        |
| Histopathology, n (%)                 |                   |
| Germinoma                             | 16 (80)           |
| NGGCT                                 | 4 (20)            |
| Serum marker, n (%)                   | 2 (10)            |
| CSF marker, n (%)                     | 6 (30)            |
| Surgery, n (%)                        | 7 (35)            |
| RT Field, n (%)                       |                   |
| ventricular system + tumor bed        | 18 (90)           |
| ventricular system                    | 2 (10)            |
| Dose cGy (ventricles)                 |                   |
| mean (SD)                             | 2540 (370.4)      |
| median (min.; max.)                   | 2520 (1800; 3060) |
| Dose cGy (tumor bed)                  |                   |
| mean (SD)                             | 3908.9 (786)      |
| median (min.; max.)                   | 3600 (3000; 5400) |
| Technique, n (%)                      |                   |
| VMAT                                  | 14 (70)           |
| IMRT                                  | 6 (30)            |
| Recurrence, n (%)                     | 3 (15)            |

NGGCT = non-germinomatous germ cell tumors; CSF = cerebrospinal fluid; RT = radiation therapy; VMAT = volumetric intensity-modulated arc radiation therapy; IMRT = intensity-modulated radiation therapy; SD = standard deviation; min = minimum; max = maximum.

https://doi.org/10.1371/journal.pone.0226350.t002
of the patients with NGGCT suffered from post-CT hematological toxicity (low blood account, especially low platelets), so she received a relative final low dose for a NGGCT (36Gy instead of 50.4/55.4 Gy), presenting early recurrence in the primary tumor site and spine. Also, this patient was considered a slow responder during the initial CT treatment and was the only one in this study to die from the disease.

When the recurrence was diagnosed, the patients received a new CT plan based on cisplatin, etoposide, and ifosfamide and 2 underwent autologous bone marrow transplants. They were then referred for RT and received craniospinal irradiation, with a boost dose to the recurrent lesions visible in the MRI. The dose distribution of one of these cases is shown in Fig 3. None of the patients presented acute or late toxicity higher than grade 1 according to the Radiation Therapy Oncology Group (RTOG) toxicity classification [20]. Two patients showed no evidence of the disease at 29 and 57 months after the last course of RT. More details on the re-irradiated patients and doses used are shown in Table 3. None of the patients were lost to follow up. S1 Table shows data from all the patients.
Discussion

We report the results of the treatment of CNS-GCT pediatric patients with neoadjuvant CT, followed by whole ventricle irradiation using IMRT. To our knowledge, this is the largest Brazilian and Latin American group of patients with CNS-GCT treated using this technology. CNS-GCT are rare entities, and there is still no consensus on the best treatment approach. Although there is some evidence that isolated radiation therapy may be effective in curing these patients [21], several studies conducted over the past two decades strongly suggest the adding of CT as the first-line treatment before definitive irradiation [22]. Germinomas have a high response rate to radiation, with long-term survival rates higher than 90% using RT alone; on the other hand, NGGCT has a worse prognosis and seems to need more intensive treatment. However, the best drug protocol to be combined with irradiation and the best way to manage the use of RT in the locoregional control of the disease are still unclear, and the

![Fig 3. Example of re-irradiation volumes showing the distribution of the craniospinal and boost doses in the recurrence sites (blue, isodose of 25 Gy; green, of 45 Gy; and red, of 60 Gy).](https://doi.org/10.1371/journal.pone.0226350.g003)

Table 3. Description of the recurrence patterns.

| Histology         | Serum Diagnostic Markers | CSF Diagnostic Markers | 1st RT (Gy) | Time to recurrence (since the end of 1st RT) | Pattern of Recurrence | 2nd RT (Gy) | Status (OS)       |
|-------------------|---------------------------|------------------------|-------------|---------------------------------------------|-----------------------|-------------|-------------------|
| Germinoma         | Negative                  | Low βHCG               | 23.4/30.6   | 6 months                                   | NGGCT†                | CSF+ Lumbar = 30.6 | Living NED (65 m) |
| NGGCT             | AFP and βHCG              | AFP and βHCG           | 25.2/36.0   | 6 months                                   | CSF+ Spine Brain      | CSI = 23.4 T7-8 = 36.0 C5-S = 45.0 | Death (28 m)      |
| NGGCT             | Negative                  | AFP and βHCG           | 30.6/50.4   | 16 months                                  | CSF+ Brain            | CSI = 36.0 Cranium = 18.0 | Living NED (59 m) |

NGGCT = non-germinomatous germ cell tumor; AFP = alpha-fetoprotein; βHCG = beta human chorionic gonadotropin; RT = radiotherapy; CSF+ = cerebrospinal fluid with positive markers; CSI = radiation therapy in the craniospinal axis; OS = overall survival; NED = no evidence of disease.

*1st RT(Gy) vent/bed = first course of radiation therapy with doses to the ventricles and the tumor bed, in Gy;

*2nd RT (Gy) = second irradiation with doses in Gy;

*patient initially diagnosed with germinoma that recurred as a NGGCT.

[https://doi.org/10.1371/journal.pone.0226350.t003](https://doi.org/10.1371/journal.pone.0226350.t003)
common late effects from craniospinal irradiation are still considered unacceptable by some experts [23].

Few randomized prospective studies have been published, and clinical decisions are often based on retrospective studies and historical data [3]. The main study (ACNS1123 COG study), which is still ongoing, intends to determine prospectively whether neoadjuvant CT followed by whole ventricle irradiation with reduced doses will succeed in maintaining the excellent historical results obtained with localized CNS-GCT treatment. In the COG study, the treatment regimen is similar to the one used in our group, with neoadjuvant CT (based on carboplatin and etoposide for PG, with the addition of ifosfamide for NGGCT) offered to the patients showing good response whole ventricle irradiation (reaching 18 Gy for PG and 30.6 Gy for NGGCT) with a tumor bed boost (reaching 30 Gy for PG and 54 Gy for NGGCT).

Other relevant studies are very heterogeneous, regarding both the number of patients and specific guidelines for each risk group. An example is one of the most robust prospective phase II studies, the SIOP CNSGCT 96: despite having a multi-institutional design involving 12 European countries, patient enrollment was difficult due to the rarity of the disease. In addition, patients were not randomized for inclusion in the treatment groups, leaving the choice of group allocation to the physician or to the institution that received them. Although there is a relatively large number of patients in Japan due to the higher incidence in Asian countries, studies carried out with Japanese patients included very distinct risk groups, with different treatment regimens and very different volumes of RT [6,8,22,24,25]. When we started treating these patients, due to the lack of prospective evidence of focal RT use versus CSI, we chose an intermediate modality using the WVI for both PG and NGGCT with localized disease, aiming to minimize the radiation dose on normal brain tissue but giving a good dose coverage to the high risk areas, the ventricles and the tumor bed [26]. Likewise, some other published studies have reported good results with local RT for this type of patient.[27–30]

Thus, even though ours is a retrospective study without a previously established dose protocol, our results are very positive, specially for the PGs, because all patients received a technically homogeneous treatment by the same team of radiation oncologists and pediatric oncologists, with the same protocol of neoadjuvant CT followed by an advanced technology RT. Additionally, considering the rarity of this disease, other important studies on CNS-GCT also included an average of 20 patients, as in our case [18,27,31–34].

Compared to Japanese, Canadian, American, and European series, we also obtained positive outcomes when we considered the two histological subtypes as distinct risk groups. For PG, we found an overall survival of 100% and disease-free survival of 93.75%, values comparable to the average values of 97–100% and 89–96%, respectively, in these international studies. More importantly, for the NGGCT a group known for its worse prognosis, we found an overall survival of 75% with disease-free survival of 50% versus 68–75% and 60–68% obtained in other comparable studies. [9,22,24,27,32].

In our patient follow-up, we observed 3 recurrences: 1 was a germinoma that recurred as non-germinomatous, and the other 2 were originally NGGCT with positive serum and CSF markers at diagnosis. Thresholds for these tumor markers are not clear-cut, leading to potential inaccuracies in diagnosis. NGGCTs are diagnosed if the AFP or HCG level are higher than certain limits defined in the CSF or serum, but some germinomas can have positive HCG in lower levels and are considered a higher risk group when compared with those that are negative for markers.[28,35]

Even with our limited sample, this recurrence pattern stands out because these two patients with recurrent disease account for 50% of all the NGGCT, and one of them, while achieving total response, received a relatively low dose for an NGGCT and was considered a slow responder to neoadjuvant CT, being the only registered death from the disease. The other
children were successfully rescued with CT and a new course of radiation (CSI) with low rates of toxicity. Taken together, the results reinforce the importance of a more rigid selection in low-dose RT protocols with fields restricted to the ventricular system, especially in patients with NGGCT that may benefit from craniospinal irradiation. A Taiwanese review of 102 cases of recurrent CNS-GCT that were successfully treated showed that initial treatment with extensive volumes and higher doses of RT can complicate salvage re-irradiation. The authors pointed out that these tumors, when recurring, are highly sensitive to radiation and/or CT, similar to naive tumors at diagnosis, and regimens combining CT with craniospinal irradiation in low doses were highly effective in obtaining sustainable control of the disease, with acceptable levels of acute and late toxicity [36].

Recently, the results of the largest prospective series of patients with intracranial malignant NGGCT, treated in the multinational European protocol SIOP-CNS-GCT-96, have reinforced the use of a more localized RT even for this group of poorer prognosis. The study showed that the combination of CT and RT for NGGCT patients, with risk-adapted RT tailored according to initial dissemination (focal for those with localized disease and CSI plus focal boost for metastatic cases), was effective at producing long-term durable treatment response [25].

On the other hand, after an interim analysis, the ACNS1123 study has closed the arm of the patients with localized NGGCTs treated with WVI prematurely, and formal reporting of the results is still awaited, showing that the optimal radiotherapy volume for localized NGGCT continues to be different globally [28]. Probably, a response-based approach would be more appropriate for the treatment of these patients.

According to QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic), younger age is the most important risk factor for neurocognitive decline in children who undergo cranial RT. Other risk factors include being female, the NF-1 mutation, an extension of the surgical resection, hydrocephalus, protocols including neurotoxic CT (especially high dose methotrexate), tumor location, and the irradiated brain volume [37].

The finding that IMRT is capable of significantly reducing the cerebral hemisphere volumes that receive elevated doses of radiation is relevant not only for this group of patients with a rare disease but also for pediatric patients with other CNS tumors [34,38]. Given the complex form, size, and central location of the ventricular system, the resulting PTV is usually irregular and large. In our population, the whole ventricle PTV size corresponded on average to 28% of the total brain volume [38]. Furthermore, the spared cerebral hemispheres concentrate a large amount of the external layer of brain tissue, the very region where the cerebral cortex is located.

There is a trend to consider proton beam RT as the technique of choice for the treatment of CNS tumors in children. Several studies have shown its dosimetric benefits and some are trying to demonstrate its long-term advantages [39]. Bearing in mind that the CNS-GCT is a rare group of malignancies, and most of the publications refer to other histology types, we could use for them the same rationale, knowing that Proton plans showed a consistent reduction in dose to the adjacent critical structures (for example: temporal lobes, hippocampi, cochlea and whole brain), supporting the potential for a reduction in late effects, neurocognitive development, and secondary malignancy risk in this population. [40–43].

Even with all the optimism and the expectations generated by the introduction of this new technology, recent publications about the cognitive assessments of these children did not demonstrate significant differences in performance compared with those treated with photons in modern protocols [44]. Alternatively, modern protocols with IMRT can be so successful in limiting the exposure of the surrounding healthy brain tissue that patients treated in these studies since 2002 are not experiencing the magnitude of neurocognitive decline reported in earlier studies [44]. So, there is still interest in the study of IMRT, especially in low-income
countries where the proton technology is still not available, considering that in comparison to the 3D RT, IMRT can also provide a consistent dose reduction to critical structures with the potential to generate a lasting impact in these children’s lives.[38]

While we wait for the results of the ACNS1123 trial that will hopefully validate whether this approach is safe in a larger cohort of prospectively followed patients, our findings provide more information to support the use of neoadjuvant CT followed by whole ventricle irradiation and a tumor bed boost in patients with localized intracranial disease.

Conclusions

The results of this study suggest that the combined use of chemotherapy followed by whole ventricle irradiation with IMRT is effective for CNS GCTs, specially PGs. Even being rescued with CSI, the NGGCT cases have markedly worse prognoses and should be more rigorously selected for localized treatment. Larger prospective studies might shed light on the more appropriate radiation doses and volumes for both PG and NGGCT, probably guided by a response-based approach.

Supporting information

S1 Table. Characteristics of the 20 patients.
(DOCX)

Acknowledgments

We thank Patricia Logullo for her kind assistance with manuscript review and comments, and Rogério Ruscitto do Prado for his assistance with the statistical analysis.

Author Contributions

Conceptualization: Ana Carolina Pires de Rezende, Eduardo Weltman, Nelson Hamerschlak.

Data curation: Ana Carolina Pires de Rezende, Eduardo Weltman, Michael Jenwei Chen, Juliana Karassawa Helito, Ícaro Thiago de Carvalho, Roberto Kenji Sakuraba, Nasjla Saba Silva, Andrea Maria Cappellano.

Formal analysis: Eduardo Weltman, Michael Jenwei Chen, Juliana Karassawa Helito, Ícaro Thiago de Carvalho, Roberto Kenji Sakuraba, Nasjla Saba Silva, Andrea Maria Cappellano, Nelson Hamerschlak.

Funding acquisition: Nelson Hamerschlak.

Investigation: Ana Carolina Pires de Rezende, Michael Jenwei Chen.

Methodology: Ana Carolina Pires de Rezende, Eduardo Weltman.

Project administration: Ana Carolina Pires de Rezende, Nelson Hamerschlak.

Supervision: Eduardo Weltman, Nelson Hamerschlak.

Writing – original draft: Ana Carolina Pires de Rezende, Eduardo Weltman.

Writing – review & editing: Ana Carolina Pires de Rezende, Eduardo Weltman, Michael Jenwei Chen, Juliana Karassawa Helito, Ícaro Thiago de Carvalho, Roberto Kenji Sakuraba, Nasjla Saba Silva, Andrea Maria Cappellano, Nelson Hamerschlak.
References

1. Rickert C, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001; 17(9):503–511. https://doi.org/10.1007/s003810010496 PMID: 11585322

2. Rosemberg S, Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1,195 cases from a single institution. Childs Nerv Syst 2005; 21(11):940–944. https://doi.org/10.1007/s00381-005-1181-x PMID: 16044344

3. Echevarría ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist 2008; 13(6):690–699. https://doi.org/10.1634/theoncologist.2008-0037 PMID: 18586924

4. Poynter JN, Fonstad R, Tolar J, Spector LG, Ross JA. Incidence of intracranial germ cell tumors by race in the United States, 1992–2009: A potential link with autoimmune encephalitis? [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington. Cancer Re. 2013;73(8 Suppl):Abstract 2291. Available from: http://cancerres. aacrjournals.org/content/73/8_Supplement/2291.short. Accessed in 2016 (Sep 27).

5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1 PMID: 27157931

6. Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997; 86(3):446–455. https://doi.org/10.3171/jns.1997.86.3.0446 PMID: 9046301

7. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, et al. CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys 2005; 62(3):803–808. https://doi.org/10.1016/j.ijrobp.2004.10.026 PMID: 15936563

8. Calaminus G, Kortmann R, Frappaz D. CNS GCT 96 protocol for intracranial localised and metastatic non-germinomatous germ cell tumors (NGGCT). [Special Issue: 43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011, Auckland, New Zealand, 28th–30th October, 2011.] Pediatr Blood Cancer 2011;57(5):743–744. [abstract].

9. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, et al. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 2010; 54(3):377–383. https://doi.org/10.1002/pbc.22381 PMID: 2063410

10. Eom KY, Kim IH, Park CI, Kim HJ, Kim JH, Kim K, et al. Upfront chemotherapy and involved-field radiotherapy results in more relapses than extended radiotherapy for intracranial germinomas: modification in radiotherapy volume might be needed. Int J Radiat Oncol Biol Phys 2006; 65(1):210–221. https://doi.org/10.1016/j.ijrobp.2005.10.038 PMID: 16472938

11. Cappellano AM, Paiva P, Cavalheiro S, Dättoli P, Seixas MT, Silva NS. Treatment of intracranial germinoma: Experience of a Brazilian institution. Neuro Oncol 2012; 14(Suppl 1):i49–55. [GC-18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483347/. Accessed in 2019 (27 Nov).

12. Khatau S, Dhali G, O’Neil S, Jubran R, Villalbaña JG, Marachelian A, et al. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer 2010; 55(1):42–46. https://doi.org/10.1002/pbc.22468 PMID: 20222020

13. Hill JM, Kornblith AB, Jones D, Freeman A, Holland JF, Glicksman AS, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998; 82(1):208–218. PMID: 9428499

14. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE, et al. Neuropsychological functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998; 16(5):1723–1728. https://doi.org/10.1200/JCO.1998.16.5.1723 PMID: 9586864

15. Merchant TE, Kiehna EN, Li C, Shukla H, Sengupta S, Xiong X, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 2006; 65(1):210–221. https://doi.org/10.1016/j.ijrobp.2005.10.038 PMID: 16472938

16. Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 2000; 48(5):1371–1380. https://doi.org/10.1016/s0360-3016(00)00772-0 PMID: 11121836

17. Silber JH, Radcliffe J, Peckham V, Perliongo G, Kishnani P, Fridman M, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992; 10(8):1390–1396. https://doi.org/10.1200/JCO.1992.10.8.1390 PMID: 1517781
18. O’Neil S, Ji L, Buranahurin C, Azoff J, Dhall G, Khatua S, et al. Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. Pediatr Blood Cancer 2011; 57(4):669–673. https://doi.org/10.1002/pbc.23146 PMID: 21495164
19. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21(1):109–122. https://doi.org/10.1016/0360-3016(91)91071-y PMID: 2032882
20. Cox JD; Stetz J; Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C PMID: 7713792
21. Shim KW, Park EK, Lee YH, Suh CO, Cho J, Choi JU, et al. Treatment strategy for intracranial primary pure germinoma. Childs Nerv Syst. 2013 Feb; 29(2):239–248. https://doi.org/10.1007/s00381-012-1902-x PMID: 22965772
22. Matsuutani M, Japanese Pediatric Brain Tumor Study Group. Combined chemotherapy and radiation therapy for CNS germ cell tumors—the Japanese experience. J Neurooncol 2001; 54(3):311–316. https://doi.org/10.1023/a:1012743707783 PMID: 11767296
23. Rogers SJ, Mosleh-Shirazi MA, Saran FH. Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 2005; 6(7):509–519. https://doi.org/10.1016/S1470-2045(05)70245-X PMID: 15992700
24. Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garré ML, et al. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 2013; 15(6):788–796. https://doi.org/10.1093/neuonc/not19 PMID: 23460321
25. Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol 2017; 19(12):1661–1672. https://doi.org/10.1093/neuonc/nox222 PMID: 29048506
26. De B, Cahlon O, Dunkel IJ, De Braganca KC, Khakoo Y, Gilheeney SW, et al. Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors. J Neurooncol 2017; 134(2):349–356. https://doi.org/10.1007/s11060-017-2532-7 PMID: 28660318
27. Robertson PL, Jakacki R, Hukin J, Siffert J, Allen JC. Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study. J Neurooncol 2014; 118(1):93–100. https://doi.org/10.1007/s11060-013-1306-0 PMID: 24700239
28. Bowzyk Al-Naeeb A, Murray M, Horan G. Current Management of Intracranial Germ Cell Tumours. Clin Oncol (R Coll Radiol) 2018; 30(4):204–214.
29. Matsuutani M. Treatment of intracranial Germ Cell Tumor in Japan: New Horizon of the Germ Cell Therapy. Seoul: The Korean Society for Pediatric Neuro-Oncology; 2013. p. 8.
30. Kim J, Park J. Understanding the Treatment Strategies of Intracranial Germ Cell Tumors: Focusing on Radiotherapy. J Korean Neurosurg Soc 2015; 57(5):315–322. https://doi.org/10.3340/jkns.2015.57.5.315 PMID: 26113957
31. Cheng S, Kilday JP, Laperriere N, Janzen L, Drake J, Bouffet E, et al. Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. J Neurooncol 2016; 127(1):173–180. https://doi.org/10.1007/s11060-015-02529-1 PMID: 26741433
32. Cahlon O, Dunkel I, Gilheeney S, Khakoo Y, Souweidane M, De Braganca K, et al. Craniospinal radiation therapy may not be necessary for localized nongerminomatous germ cell tumors (NGGCT). International Journal of Radiation Oncology Biology Physics. 2014; 90 (1 Supplement): S723–S724. https://doi.org/10.1093/ijrobp/ntu171 PMID: 24700239
33. Yang JC, Terezakis SA, Dunkel IJ, Gilheeney SW, Wolden SL. Intensity-Modulated Radiation Therapy With Dose Painting: A Brain-Sparing Technique for Intracranial Germ Cell Tumors. Pediatr Blood Cancer. 2016; 63(4):646–51. https://doi.org/10.1002/pbc.25867 PMID: 26703370
34. Murray MJ, Bartels U, Nishikawa R. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 2015; 16(9):e470–e477. https://doi.org/10.1016/S1470-2045(15)00244-2 PMID: 26370356
35. Hu YW, Huang PI, Wong TT, Ho DM, Chang KP, Guo WY, et al. Salvage treatment for recurrent intracranial germinoma after reduced-volume radiotherapy: a single-institution experience and review of the
37. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl):S20–7. https://doi.org/10.1016/j.ijrobp.2009.02.091 PMID: 20171513

38. Chen MJ, Santos Ada S, Sakuraba RK, Lopes CP, Gonçalves VD, Weltman E, et al. Intensity-modulated and 3D-conformal radiotherapy for whole-ventricular irradiation as compared with conventional whole-brain irradiation in the management of localized central nervous system germ cell tumors. Int J Radiat Oncol Biol Phys 2010; 76(2):608–614. https://doi.org/10.1016/j.ijrobp.2009.06.028 PMID: 19879065

39. Ladra MM, MacDonald SM, Terezakis SA. Proton therapy for central nervous system tumors in children. Pediatr Blood Cancer 2018; 65(7):e27046. https://doi.org/10.1002/pbc.27046 PMID: 29630784

40. St Clair WH, Adams JA, Bues M. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58(3):727–34. https://doi.org/10.1016/S0360-3016(03)01574-8 PMID: 14967427

41. Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 2016; 17(3):287–98. https://doi.org/10.1016/S1470-2045(15)00167-9 PMID: 26830377

42. Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, Allen PK, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014; 90(2):354–61. https://doi.org/10.1016/j.ijrobp.2014.05.051 PMID: 25052561

43. Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness—should we revise current clinical practice? Int J Radiat Oncol Biol Phys 2015; 91(5):892–4. https://doi.org/10.1016/j.ijrobp.2014.11.021 PMID: 25832682

44. Kahalley LS, Ris MD, Grosshans DR, Okcu MF, Paulino AC, Chintagumpala M, et al. Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. J Clin Oncol 2016; 34(10):1043–1049. https://doi.org/10.1200/JCO.2015.62.1383 PMID: 26811522